Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing–remitting multiple sclerosis

Cost effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis

(2012) Stephanie R. Earnshaw et al.   Applied Health Economics and Health Policy

Functional role of brain-derived neurotrophic factor in neuroprotective autoimmunity: therapeutic implications in a model of multiple sclerosis

(2011) R. A. Linker et al.   BRAIN

Neuroinflammation and Neuroprotection: An Update on (Future) Neurotrophin-Related Strategies in Multiple Sclerosis Treatment

(2011) L. De Santi et al.   CURRENT MEDICINAL CHEMISTRY

The impact of intensity variations in T1-hypointense lesions on clinical correlations in multiple sclerosis

(2011) RC Tam et al.   Multiple Sclerosis Journal

A critical appraisal of treatment decisions in multiple sclerosis—old versus new

(2011) Bernd C. Kieseier et al.   Nature Reviews Neurology

Phase III dose-comparison study of glatiramer acetate for multiple sclerosis

(2010) Giancarlo Comi et al.   ANNALS OF NEUROLOGY

Effects of glatiramer acetate on spasticity in previously interferon-β-treated and treatment-naive patients with relapsing-remitting multiple sclerosis: A prospective, nonrandomized, open-label, uncontrolled, observational pilot study

(2010) José Eustasio Meca-Lallana et al.   CLINICAL THERAPEUTICS

Interferon-β-1b

(2010) Greg L. Plosker   CNS DRUGS

Comparing costs and absences for multiple sclerosis among US employees: pre- and post-treatment initiation

(2010) Krithika Rajagopalan et al.   CURRENT MEDICAL RESEARCH AND OPINION

The Potential Role of B Cell-Targeted Therapies in Multiple Sclerosis

(2010) Aaron Boster et al.   DRUGS

Long-term treatment of multiple sclerosis with glatiramer acetate: Natural history of the subtypes of anti-glatiramer acetate antibodies and their correlation with clinical efficacy

(2010) Dimitros Karussis et al.   JOURNAL OF NEUROIMMUNOLOGY

Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate

(2010) C. Ford et al.   Multiple Sclerosis Journal

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

(2010) Ludwig Kappos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis

(2010) Jeffrey A. Cohen et al.   NEW ENGLAND JOURNAL OF MEDICINE

B cells from glatiramer acetate-treated mice suppress experimental autoimmune encephalomyelitis

(2009) Mrinalini Kala et al.   EXPERIMENTAL NEUROLOGY

Long-Term Study of Brain1H-MRS Study in Multiple Sclerosis: Effect of Glatiramer Acetate Therapy on Axonal Metabolic Function and Feasibility of Long-Term1H-MRS Monitoring in Multiple Sclerosis

(2009) Omar Khan et al.   JOURNAL OF NEUROIMAGING

New acute and chronic black holes in patients with multiple sclerosis randomised to interferon beta-1b or glatiramer acetate

(2009) D Cadavid et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial

(2009) G Comi et al.   LANCET

250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

(2009) Paul O'Connor et al.   LANCET NEUROLOGY

Disease progression among multiple sclerosis patients before and during a disease-modifying drug program: a longitudinal population-based evaluation

(2009) PJ Veugelers et al.   Multiple Sclerosis Journal

Glatiramer acetate in combination with minocycline in patients with relapsing—remitting multiple sclerosis: results of a Canadian, multicenter, double-blind, placebo-controlled trial

(2009) LM Metz et al.   Multiple Sclerosis Journal

GLANCE: Results of a phase 2, randomized, double-blind, placebo-controlled study

(2009) A. D. Goodman et al.   NEUROLOGY

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

(2008) Daniel D Mikol et al.   LANCET NEUROLOGY

Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis

(2008) T Vollmer et al.   Multiple Sclerosis Journal

Long-term (up to 22 years), open-label, compassionate-use study of glatiramer acetate in relapsing—remitting multiple sclerosis

(2008) Aaron Miller et al.   Multiple Sclerosis Journal